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Th   e ERBB receptor family encompasses four trans  mem-
brane tyrosine kinases that regulate cell diﬀ  erentiation, 
mitogenesis, survival, and migration. Dysregulated func-
tion of these receptor tyrosine kinases has been shown to 
result in cell transformation and cancer [1]. Th  is  receptor 
family includes the epidermal growth factor receptor 
(EGFR/ERBB1), HER2/ERBB2, HER3/ERBB3, and HER4/
ERBB4. Signaling is triggered by ligand binding to the 
extracellular domain of EGFR, ERBB3, and ERBB4, 
resulting in a conformational change in the receptor 
ectodomains and the dimerization of their cytoplasmic 
tyrosine kinase domains [2]. Th  e receptor–receptor 
association releases the kinase domain from a default 
autoinhibited state, leading to transphosphorylation of 
tyrosine residues in the receptor C-terminus [3]. In turn, 
these phosphorylated tyrosines become docking sites for 
the speciﬁ   c binding of cytoplasmic signaling proteins 
containing Src homology-2 and protein tyrosine-binding 
domains, which then trigger several intracellular signal-
ing pathways associated with cell growth and trans-
formation [4].
Dimerization and activation of the tyrosine kinase 
domain of ERBB receptors are highly regulated processes 
modulated by incompletely understood stimulatory and 
inhibitory inputs. Recent data suggest that the mere 
dimerization of EGFR is not suﬃ   cient for their activation 
[5]. Further, only a fraction of dimerized receptors 
appears catalytically active, particularly those receptors 
where the kinase domains are arranged as asymmetric 
dimers [6,7]. Th  ese data coupled with the observation 
that receptor dimers may occur in the absence of ligand 
[5] led to speculation on the presence of cytoplasmic 
activators that modulate the conversion of these receptor 
dimers into an active state.
Th  e study by Bill and colleagues now reports that 
cytohesins – guanine-nucleotide exchange factors of the 
ATP ribosylation factors involved in vesicular traﬃ   cking, 
cell migration, and cytoskeletal dynamics – facilitate 
conformational rearrangements in the cytoplasmic 
domain of ERBB receptors, leading to their activation [8]. 
Th   e cytohesin family consists of four highly homologous 
proteins, the ubiquitous cytohesin-1, cytohesin-2 
(ARNO), cytohesin-3 (Grp), and cytohesin-4, exclusively 
expressed by immune cells [9]. In this paper, over-
expression of ARNO increased EGFR phosphorylation 
and this eﬀ  ect was also seen with a guanine-nucleotide 
exchange factor-inactive ARNO mutant. Receptor kinase 
activation was not associated with nor required receptor 
dimerization or endocytosis, suggesting a possible role 
for ARNO in asymmetric dimer formation. Using 
ﬂ  uorescence resonance energy transfer and ﬂ  uorescently 
labeled C-terminal EGFR fragments, Bill and colleagues 
showed that ARNO modulates the inter  action between 
the two receptors in the dimer. Subse  quent experiments 
suggested ARNO binds dimerized EGFR at the kinase or 
juxtamembrane regions. Similar eﬀ  ects were observed on 
endogenous, already dimerized ERBB2/ERBB3 receptors 
upon overexpression of ARNO into SKBR3 cells.
Tissue levels of ARNO were evaluated by immuno-
histochemistry in a cohort of primary lung adeno-
carcinomas. Staining with ARNO antibodies appeared 
higher in the cancers compared with normal lung tissues. 
Further, tissue levels of the cytohesin correlated with 
levels of P-EGFR, P-ERK, and P-AKT also measured by 
immunohistochemistry. Inhibition of ARNO with the 
cytohesin inhibitor SecinH3 or siRNA reduced basal 
EGFR phosphorylation/activation and growth of EGFR-
dependent human lung adenocarcinoma cells in vitro. 
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cytohesin protein family. These data highlight a novel 
mechanism of amplifi  cation of ERBB receptor signaling 
output that may contribute to embryogenesis and 
cancer progression.
© 2010 BioMed Central Ltd
ERBB receptors in cancer: signaling from the inside
Carlos L Arteaga1,2,3*
VIEWPOINT
*Correspondence: carlos.arteaga@vanderbilt.edu
1Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University 
School of Medicine, Division of Hematology/Oncology, VUMC, 2220 Pierce Avenue, 
777 PRB, Nashville, TN 37232-6307, USA
Full list of author information is available at the end of the article
Arteaga Breast Cancer Research 2011, 13:304 
http://breast-cancer-research.com/content/13/2/304
© 2011 BioMed Central LtdFurther, administration of SecinH3 to nude mice bearing 
PC9 lung cancer xenografts inhibited tumor cell prolifera-
tion measured by [18F]-ﬂ  uoro-l-thymidine uptake positron 
emission tomography and Ki67 immunohisto  chemistry 
as well as inducing tumor cell apoptosis assessed by 
terminal deoxynucleotidyl transferase dUTP nick end-
labeling analysis. PC9 cells harbor a gain-of-function 
activating mutant of EGFR [10], which suggests the 
facilitating role of ARNO on ERBB signaling is not 
limited to wild-type receptors.
Th  ese studies have important implications for cancer 
biology and therapy as they identify a novel mechanism 
usurped by transformed cells to amplify ERBB receptor 
signaling from the cytoplasmic side, and thus increase 
the number of actively signaling ERBB dimers within the 
pool of ligand-occupied receptors. As such, over  expres-
sion of cytohesins would provide a gain-of-ﬁ  tness  to 
ERBB signaling output that can be utilized by cancer cells 
in stressful situations such as fragile windows during 
metastatic progression and/or when they are exposed to 
anti-cancer therapies. Th   is role of cytohesins may extend 
to heterologous receptors as suggested by the fact that 
SecinH3 reduced phosphorylation of IRS-1, a main signal 
transducer of insulin and IGF-I receptor tyrosine kinases, 
in H460 lung cancer cells [8]. Future studies should also 
address whether ARNO overexpression occurs over a 
wider range of ERBB-dependent cancers. Th  e  experi  ments 
with ERBB2 gene-ampliﬁ  ed and ERBB2-dependent SKBR3 
cells suggest that cytohesins can also ﬁ  ne tune signaling 
by (asymmetric) ERBB2/ERBB3 dimers, where the potent 
ERBB2 kinase activates the catalytically deﬁ  cient kinase 
domain of ERBB3. Th  ese heterodimers are the most 
potent signaling complexes of the ERBB family [4] and 
are critical for the viability of breast cancer cells with 
ERBB2 gene ampliﬁ  cation [11,12]. Whether overexpre-
ssion of cytohesins, by amplifying ERBB signaling, 
dampens the response to tyrosine kinase inhibitors or 
receptor antibodies approved for the treatment of ERBB-
dependent tumors remains to be studied.
In summary, the elegant paper by Bill and colleagues 
shows that cytohesins promote ERBB receptor signaling 
by facilitating the formation of asymmetric dimers. For 
those interested in translational research, these data 
introduce other assays that can be incorporated into 
metrics aimed at measuring ERBB receptor output in 
tumor tissues in situ, such as the tumor content of 
cytohesins. Finally, the data suggest inside activators of 
ERBB receptor signal transduction as therapeutic targets 
that may also need to be interrupted in order to have a 
maximal eﬀ  ect for currently approved anti-ERBB recep-
tor therapies.
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